The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.
Discordance between patient and physician global assessment scores is common in SSc, with each incorporating different factors when assessing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results